Stock NAOV NANOVIBRONIX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News NanoVibronix, Inc.

Equities

NAOV

US63008J6038

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-23 pm EDT 		5-day change 1st Jan Change
0.77 USD +3.34% Intraday chart for NanoVibronix, Inc. -0.17% -33.04%
Apr. 08 NanoVibronix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 NanoVibronix, Inc. Enters into Letter of Intent with APOGEPHA Arzneimittel GmbH to Explore European Distribution Opportunity CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
NanoVibronix : Failure to Satisfy Listing Rule - Form 8-K
PU
NanoVibronix Issues Letter to Stockholders
BU
NanoVibronix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
NanoVibronix Signs Agreement for Research and Development of Next Generation PainShield and UroShield
BU
NanoVibronix Featured in Your Bladder Health Magazine
BU
NanoVibronix Enters into Letter of Intent with APOGEPHA Arzneimittel GmbH to Explore European Distribution Opportunity
BU
NanoVibronix, Inc. Enters into Letter of Intent with APOGEPHA Arzneimittel GmbH to Explore European Distribution Opportunity
CI
NanoVibronix Announces Agreement for Clinical Study of UroShield at the University of Michigan
BU
NanoVibronix, Inc. Signs Research Agreement for Clinical Study of UroShield with University of Michigan
CI
NanoVibronix Regains Nasdaq Compliance
BU
NanoVibronix Issues Letter to Shareholders
BU
NanoVibronix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
NanoVibronix UroShield Products Available on NHS Drug Tariff Effective November 1
BU
Investors Eye Fed Moves as US Futures Trend Lower in Friday's Premarket
MT
NanoVibronix Gains Approval for Inclusion of UroShield Products in NHS Prescription Services Drug Tariff
AQ
NanoVibronix Gains Approval for Inclusion of UroShield Products in NHS Prescription Services’ Drug Tariff
BU
NanoVibronix, Inc. Gains Approval for Inclusion of UroShield Products in NHS Prescription Services' Drug Tariff
CI
NanoVibronix Files Registration Statement on Behalf of Selling Shareholders
MT
NanoVibronix Announces Presentation of Positive Independent Testing Results of UroShield at ICS Annual Meeting
BU
NanoVibronix to Raise $5 Million Through Securities Placement
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NAOV Stock
  4. News NanoVibronix, Inc.